2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR

FGFR

Fibroblast growth factor receptor

FGFR

Related Products

PDF 1.46 MB

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147713
    FGFR3-IN-1
    		Inhibitor
    FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor, with IC50s of 40 nM, 5.1 nM, and 12 nM for FGFR1, 2, and 3, respectively. FGFR3-IN-1 can be used for the research of bladder cancer.
    FGFR3-IN-1
  • HY-174981
    LC-MF-4
    		Degrader
    LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research. Pink: FGFR3 ligand (HY-175414); Blue: VHL ligase ligand (HY-125905); Black: linker (HY-Y1224)
    LC-MF-4
  • HY-E70819
    FGFR2 K659N Recombinant Human Active Protein Kinase
    FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659N is a mutant of FGFR3. FGFR2 K659N Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659N protein that can be used to study FGFR2 K659N-related functions.
    FGFR2 K659N Recombinant Human Active Protein Kinase
  • HY-147684
    FGFR-IN-7
    		Modulator
    FGFR-IN-7 (compound 17) is an orally active, potent and BBB-penetrated FGFR (fibroblast growth factor receptor) modulator. FGFR-IN-7 shows neuroprotective activity. FGFR-IN-7 improves brain exposure and reduced risk of phospholidosis. FGFR-IN-7 can be used for neurodegenerative diseases research.
    FGFR-IN-7
  • HY-161326
    CXF-007
    		Inhibitor
    CXF-007 is a potent and specific FGFR4 inhibitor with a IC50 value of 7 nM. CXF-007 has antitumor activity.
    CXF-007
  • HY-E70721
    FGFR4 N535K Recombinant Human Active Protein Kinase
    FGFR4 is a transcriptional target of the PAX3-FOXO1 fusion gene. FGFR4 expression is significantly higher in rhabdomyosarcoma. FGFR3 K650E is a mutant of FGFR3 that may be present in rhabdomyosarcoma. FGFR4 N535K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions.
    FGFR4 N535K Recombinant Human Active Protein Kinase
  • HY-RS04913
    Fgfr1 Rat Pre-designed siRNA Set A
    		Inhibitor

    Fgfr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fgfr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fgfr1 Rat Pre-designed siRNA Set A
  • HY-E70816
    FGFR2 K641N Recombinant Human Active Protein Kinase
    FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K641N is a mutant of FGFR3. FGFR2 K641N Recombinant Human Active Protein Kinase is a recombinant FGFR2 K641N protein that can be used to study FGFR2 K641N-related functions.
    FGFR2 K641N Recombinant Human Active Protein Kinase
  • HY-N0060S1
    Ferulic acid-13C3
    		Inhibitor 98.3%
    Ferulic acid-13C3 is the 13C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
    Ferulic acid-<sup>13</sup>C<sub>3</sub>
  • HY-169623
    FGFR1 inhibitor-14
    		Inhibitor
    FGFR1 inhibitor-14 (compound 28) is a FGFR1 inhibitor, which can be used in anti-cancer research.
    FGFR1 inhibitor-14
  • HY-12009R
    Pazopanib Hydrochloride (Standard)
    		Inhibitor
    Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
    Pazopanib Hydrochloride (Standard)
  • HY-P991583
    GP369
    		Inhibitor
    GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.
    GP369
  • HY-170919
    FGFR2/3-IN-2
    		Inhibitor
    FGFR2/3-IN-2 (compound 10) is an orally active FGFR2 and FGFR3 inhibitor. FGFR2/3-IN-2 inhibits FGFR2 and FGFR3 with IC50s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model.
    FGFR2/3-IN-2
  • HY-10209AR
    Masitinib mesylate (Standard)
    		Inhibitor
    Masitinib (mesylate) (Standard) is the analytical standard of Masitinib (mesylate). This product is intended for research and analytical applications. Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.
    Masitinib mesylate (Standard)
  • HY-165603
    Si5-N14
    		Inhibitor
    Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases.
    Si5-N14
  • HY-50905R
    Dovitinib (Standard)
    		Inhibitor
    Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity.
    Dovitinib (Standard)
  • HY-105279
    α-Trinositol
    		Inhibitor
    α-Trinositol (PP 56) is an isomer of the intracellular messenger IP3. α-Trinositol can be used in the study of in vitro cytotoxicity and glutamate-induced glial cytotoxic swelling and injury.
    α-Trinositol
  • HY-11106R
    Nintedanib esylate (Standard)
    		Inhibitor
    Nintedanib esylate (Standard) is the analytical standard of Nintedanib esylate. This product is intended for research and analytical applications. Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib esylate (Standard)
  • HY-10331R
    Regorafenib (Standard)
    		Inhibitor
    Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity.
    Regorafenib (Standard)
  • HY-13311R
    Infigratinib (Standard)
    		Inhibitor
    Infigratinib (Standard) is the analytical standard of Infigratinib. This product is intended for research and analytical applications. Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
    Infigratinib (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity